Carunchio 1995.

Methods	RCT Open‐label Loss to follow‐up reported: yes
Participants	Recurrent AF (type: NS) with > 3 episodes in previous 1 year. NS. n = 66 Men: 50% Age (mean): 48 (range 30–69) years Structural heart disease: 65%. LAD: 36 mm. LVEF: NS, all > 40%
Interventions	Flecainide 200 mg/day vs sotalol 240 mg/day vs placebo Method of AF cardioversion: pharmacological 67%, electrical 33% Warfarin discretionary
Outcomes	At 12 months: Mortality Stroke Proarrhythmia Adverse effects AF recurrence
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were "randomly allocated", but the procedure was not described.
Allocation concealment (selection bias)	Unclear risk	The procedure to conceal allocations was not described.
Blinding (performance bias and detection bias) All outcomes	High risk	No blinding described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No participants loss to follow‐up.
Selective reporting (reporting bias)	Low risk	All study's prespecified outcomes of interest were reported. All main outcomes expected were reported.
Other bias	Low risk	No other bias apparent.